SG11202107995SA - Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof - Google Patents

Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof

Info

Publication number
SG11202107995SA
SG11202107995SA SG11202107995SA SG11202107995SA SG11202107995SA SG 11202107995S A SG11202107995S A SG 11202107995SA SG 11202107995S A SG11202107995S A SG 11202107995SA SG 11202107995S A SG11202107995S A SG 11202107995SA SG 11202107995S A SG11202107995S A SG 11202107995SA
Authority
SG
Singapore
Prior art keywords
antibodies
tnfa
specificity
methods
targeting
Prior art date
Application number
SG11202107995SA
Inventor
David Urech
Tea Gunde
Sebastian Meyer
Christian Hess
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP19154852.8A external-priority patent/EP3689907A1/en
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of SG11202107995SA publication Critical patent/SG11202107995SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG11202107995SA 2019-01-31 2020-01-31 Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof SG11202107995SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19154846 2019-01-31
EP19154852.8A EP3689907A1 (en) 2019-01-31 2019-01-31 Antibodies targeting il-17a and methods of use thereof
EP19154850 2019-01-31
PCT/EP2020/052481 WO2020157305A1 (en) 2019-01-31 2020-01-31 Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202107995SA true SG11202107995SA (en) 2021-08-30

Family

ID=69192095

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107995SA SG11202107995SA (en) 2019-01-31 2020-01-31 Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof

Country Status (11)

Country Link
US (1) US20220127350A1 (en)
EP (1) EP3917954A1 (en)
JP (1) JP2022523908A (en)
KR (1) KR20210122243A (en)
CN (1) CN113631574A (en)
AU (1) AU2020215795A1 (en)
CA (1) CA3127935A1 (en)
IL (1) IL284644A (en)
MA (1) MA54857A (en)
SG (1) SG11202107995SA (en)
WO (1) WO2020157305A1 (en)

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
NO309690B1 (en) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonator type exploding wire for use with a perforation tool in a well
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
JP3614866B2 (en) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド Artificial antibody polypeptide
DE19819846B4 (en) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalent antibody constructs
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003301882A1 (en) 2002-11-01 2004-06-07 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
EP3260465A1 (en) 2005-06-07 2017-12-27 ESBATech, an Alcon Biomedical Research Unit LLC Stable and soluble antibodies inhibiting tnf-alpha
WO2007070750A1 (en) 2005-12-13 2007-06-21 Eli Lilly And Company Anti-il-17 antibodies
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
KR101218484B1 (en) 2006-08-11 2013-01-04 머크 샤프 앤드 돔 코포레이션 Antibodies to il-17a
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
PL2307458T3 (en) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanization of rabbit antibodies using a universal antibody framework
RU2567100C2 (en) 2008-06-25 2015-10-27 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
EP2303230A2 (en) 2008-07-10 2011-04-06 ESBATech, an Alcon Biomedical Research Unit LLC Methods and compositions for enhanced delivery of macromolecules
EP2331575B1 (en) 2008-09-29 2014-05-28 Roche Glycart AG Antibodies against human il 17 and uses thereof
PE20121094A1 (en) * 2009-03-05 2012-09-13 Abbvie Inc IL-17 BINDING PROTEINS
RU2595385C2 (en) 2010-08-05 2016-08-27 Анаптисбайо, Инк. Antibodies directed against il-17
EP2771361A1 (en) 2011-10-24 2014-09-03 AbbVie Inc. Bispecific immunobinders directed against tnf and il-17
US9676847B2 (en) 2012-06-25 2017-06-13 Orega Biotech IL-17 antagonist antibodies
EP2711016A1 (en) 2012-09-21 2014-03-26 Covagen AG Novel IL-17A binding molecules and medical uses thereof
PL2953969T3 (en) 2013-02-08 2020-02-28 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
TW201444867A (en) 2013-03-08 2014-12-01 Lilly Co Eli Anti-TNF-anti-IL-17 bispecific antibodies
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
SG11201509899PA (en) 2013-06-26 2016-01-28 Numab Ag Novel antibody frameworks
WO2015014979A1 (en) 2013-08-01 2015-02-05 F. Hoffmann-La Roche Ag Tnfa-il-17 bispecific antibodies
CA2929662C (en) 2013-11-18 2023-05-02 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-17a binding agent and uses thereof
RU2577228C2 (en) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Anti-il-17 antibodies, methods of their production and application
RU2609627C2 (en) 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" High affinity and aggregationally stable antibodies based on vl variable domains and vhh derivative
GB201500463D0 (en) 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
CN105315371B (en) * 2015-03-05 2018-05-29 北京百特美博生物科技有限公司 Anti-human IL-17 monoclonal antibodies
EP3307776A1 (en) 2015-06-15 2018-04-18 Numab Innovation AG Hetero-dimeric multi-specific antibody format
RU2020124276A (en) 2015-10-19 2021-08-03 Новартис Аг METHODS FOR TREATMENT OF NONRENTGENOGRAPHIC AXIAL SPONDILOARTHRITIS USING INTERLEUKIN-17 (IL-17) ANTAGONISTS
CN105542011A (en) * 2015-11-18 2016-05-04 北京嘉泰先科医药科技有限公司 Bispecific or multispecific Ig JR binding protein
GB201522391D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
MA46681A (en) 2016-01-28 2019-09-11 Janssen Biotech Inc ANTI-TNF-ALPHA / IL-17A BISPECIFIC ANTIBODIES ANTIBODIES AND ANTI-TNF-ALPHA ANTIBODIES AND METHODS FOR USING THEM
EP3430044A1 (en) * 2016-03-17 2019-01-23 Numab Innovation AG Anti-tnf alpha -antibodies and functional fragments thereof
CN107488227A (en) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 Anti-human IL-17 A monoclonal antibodies, its preparation method and application
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
WO2018224439A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
EP3635014B1 (en) * 2017-06-05 2023-09-27 Numab Therapeutics AG Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa
CN109206515B (en) * 2017-07-06 2021-10-12 北京伟峰益民科技有限公司 Fully human anti-human interleukin 17A antibody and application thereof

Also Published As

Publication number Publication date
CA3127935A1 (en) 2020-08-06
MA54857A (en) 2021-12-08
AU2020215795A1 (en) 2021-07-29
US20220127350A1 (en) 2022-04-28
WO2020157305A1 (en) 2020-08-06
IL284644A (en) 2021-08-31
KR20210122243A (en) 2021-10-08
EP3917954A1 (en) 2021-12-08
CN113631574A (en) 2021-11-09
JP2022523908A (en) 2022-04-27

Similar Documents

Publication Publication Date Title
EP3743063A4 (en) Inhibitors of cbl-b and methods of use thereof
EP3612551A4 (en) Variants of cpf1 (cas12a) with altered pam specificity
IL287468A (en) Nucleic acid constructs and methods for their manufacture
EP4031177A4 (en) Anti-tnfr2 antibodies and methods of use
EP4045643A4 (en) Variants of cas12a nucleases and methods of making and use thereof
SG11202009692SA (en) Multispecific antibodies and use thereof
IL273841A (en) Antibodies targeting cd137 and methods of use thereof
MA44061A (en) MULTISPECIFIC ANTIBODY MOLECULES WITH SPECIFICITY FOR TNF-ALPHA, IL-17A AND IL-17F
IL291325A (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
IL290741A (en) Anti-cd96 antibodies and methods of use thereof
EP3644062A4 (en) Method for predicting response of esophagus cancer to anti-erbb3 antibody therapy, and kit
IL287282A (en) Anti-mertk antibodies and their methods of use
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
IL304403A (en) Multispecific antibodies having specificity for ror1 and cd3
ZA202208798B (en) Anti-tigit antibodies, multispecific antibodies comprising the same and methods of using the same
IL289952A (en) Anti-ms4a4a antibodies and methods of use thereof
KR20220035450A (en) IRAK inhibitors and methods for their preparation and use
SG11202108403UA (en) Anti-clec2d antibodies and methods of use thereof
ZA202208799B (en) Anti-tigit antibodies, multispecific antibodies comprising the same and methods of using the same
EP3754021A4 (en) Aptamer for sclerostin and use thereof
IL291461A (en) Anti-alpha-synuclein antibodies and methods of use thereof
EP3755689A4 (en) Inhibitors of egfr and methods of use thereof
EP3704248A4 (en) Methods and kits for targeted enrichment of target dna with high gc content
EP4076522A4 (en) Anti-bcma car antibodies, conjugates, and methods of use
EP4061848A4 (en) Anti-ror-2 antibodies and methods of use